INT119905

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.18
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 14
Disease Relevance 5.00
Pain Relevance 1.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE3A) signal transduction (PDE3A) lipid metabolic process (PDE3A)
Anatomy Link Frequency
myocytes 2
smooth muscle 2
heart 1
PDE3A (Homo sapiens)
Pain Link Frequency Relevance Heat
Restless leg syndrome 2 99.78 Very High Very High Very High
adenocard 36 99.46 Very High Very High Very High
Inflammation 380 98.88 Very High Very High Very High
cINOD 10 98.44 Very High Very High Very High
cva 1 96.32 Very High Very High Very High
fibrosis 10 71.32 Quite High
Inflammatory mediators 40 63.28 Quite High
antagonist 10 60.12 Quite High
abdominal pain 10 27.08 Quite Low
headache 13 26.44 Quite Low
Disease Link Frequency Relevance Heat
Peripheral Arterial Disease 1 99.92 Very High Very High Very High
Increased Venous Pressure Under Development 46 99.78 Very High Very High Very High
INFLAMMATION 440 98.88 Very High Very High Very High
Pulmonary Disease 310 98.12 Very High Very High Very High
Cv General 4 Under Development 1 96.84 Very High Very High Very High
Hypertension 50 93.56 High High
Asthma 20 91.56 High High
Apoptosis 10 79.00 Quite High
Hypoxia 10 78.64 Quite High
Disease 60 77.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Siguazodan, a PDE3 inhibitor, potentiated relaxation induced by rolipram suggesting an interaction between PDE3 inhibition and PDE4 inhibition (Torphy et al 1993).
Negative_regulation (inhibition) of PDE3
1) Confidence 0.18 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.31 Pain Relevance 0.09
PDE3 can be inhibited by a number of drugs, including cilostamide, enoximone, and lixazinone.
Negative_regulation (inhibited) of PDE3
2) Confidence 0.18 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.20 Pain Relevance 0.06
Similarly, although PDE3 inhibitors do not appear to have direct anti-inflammatory actions, they appear to augment the anti-inflammatory actions of PDE4 inhibitors (Robicsek et al 1991; Schudt et al 1995; Giembycz et al 1996).


Negative_regulation (inhibitors) of PDE3 associated with inflammation
3) Confidence 0.18 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.33 Pain Relevance 0.10
Given their tissue distribution, in particular their presence in pulmonary and vascular smooth muscle, it is possible that inhibition of PDE3 and PDE5 could be of benefit in patients with COPD.
Negative_regulation (inhibition) of PDE3 in smooth muscle associated with pulmonary disease
4) Confidence 0.18 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 1.08 Pain Relevance 0.14
Although inhibitors of PDE3 have little intrinsic anti-inflammatory action they do appear to augment the anti-inflammatory properties of PDE4 inhibitors (Robicsek et al 1991; Giembycz et al 1996; Schudt et al 1995).
Negative_regulation (inhibitors) of PDE3 associated with inflammation
5) Confidence 0.18 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.48 Pain Relevance 0.22
It has been previously shown that cilostazol (Pletal), a drug for relief of symptoms of intermittent claudication, potently inhibits cyclic nucleotide phosphodiesterase type 3 (PDE3) and moderately inhibits adenosine uptake.
Negative_regulation (inhibits) of PDE3 associated with adenocard and restless leg syndrome
6) Confidence 0.17 Published 2004 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 15243309 Disease Relevance 0.18 Pain Relevance 0.31
PDE3 inhibitors may be clinically useful in the treatment of delayed cerebral vasospasm after subarachnoid hemorrhage.
Negative_regulation (inhibitors) of PDE3 associated with cv general 4 under development, cva and increased venous pressure under development
7) Confidence 0.15 Published 2004 Journal J. Cereb. Blood Flow Metab. Section Abstract Doc Link 15625409 Disease Relevance 0.29 Pain Relevance 0.05
PDE3 inhibitors enhance myocardial contractility and induce vascular and airway smooth muscle relaxation (Leeman et al 1987; Myou et al 1999; Fujimura et al 1995).
Negative_regulation (inhibitors) of PDE3 in smooth muscle
8) Confidence 0.13 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.21 Pain Relevance 0.07
PDE4 is not inhibited by cGMP and thus originally PDE3 was called cGMP-inhibited PDE to distinguish it from PDE4. cGMP inhibition of PDE3 may be physiologically relevant to the elevation of cAMP levels in a variety of cells including human myocytes, where nitric oxide induced relaxation may be mediated by activation of guanylyl cyclase, elevation of intracellular cGMP levels and inhibition of PDE3 leading to elevated cAMP levels (Kirstein et al 1995).
Negative_regulation (inhibition) of PDE3 in myocytes
9) Confidence 0.13 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.15 Pain Relevance 0.03
Thus, in theory, inhibitors of PDE3 could act both as bronchodilators and anti-inflammatory drugs and may have synergistic effects with PDE4 inhibitors.
Negative_regulation (inhibitors) of PDE3 associated with inflammation and cinod
10) Confidence 0.13 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 1.10 Pain Relevance 0.32
PDE4 is not inhibited by cGMP and thus originally PDE3 was called cGMP-inhibited PDE to distinguish it from PDE4. cGMP inhibition of PDE3 may be physiologically relevant to the elevation of cAMP levels in a variety of cells including human myocytes, where nitric oxide induced relaxation may be mediated by activation of guanylyl cyclase, elevation of intracellular cGMP levels and inhibition of PDE3 leading to elevated cAMP levels (Kirstein et al 1995).
Negative_regulation (inhibition) of PDE3 in myocytes
11) Confidence 0.13 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.19 Pain Relevance 0
Siguazodan, a PDE3 inhibitor, potentiated relaxation induced by rolipram suggesting an interaction between PDE3 inhibition and PDE4 inhibition (Torphy et al 1993).
Negative_regulation (inhibitor) of PDE3
12) Confidence 0.13 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.29 Pain Relevance 0.08
It elevates extracellular adenosine concentration, by inhibiting adenosine uptake, and combines with PDE3 inhibition to augment inhibition of platelet aggregation and vasodilation while attenuating positive chronotropic and inotropic effects on the heart.
Negative_regulation (inhibition) of PDE3 in heart associated with adenocard and increased venous pressure under development
13) Confidence 0.13 Published 2004 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 15243309 Disease Relevance 0.19 Pain Relevance 0.31
NO donors and selective inhibitors of PDE3 and PDE5 induce migraine-like headache and play a role in endothelial dysfunction during stroke.
Negative_regulation (inhibitors) of PDE3
14) Confidence 0.06 Published 2010 Journal Headache Section Body Doc Link 19751368 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox